Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS)
Publication date: Available online 15 November 2026 Source: Drug and Alcohol Dependence Author(s): Zhao Liu, Ting-fen Ji, An-qi Cheng, Min Wang, Qing-qing Song, Xin-mei Zhou, Xue Yu, Liang Zhao, Dan Xiao, Chen Wang
Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS). // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626004114?dgcid=rss_sd_all
Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS). Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626004114?dgcid=rss_sd_all
“Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS).” Drug and Alcohol Dependence.
@article{article43470,
title = {Comparative effectiveness and safety of generic versus brand-name Varenicline for smoking cessation in Chinese population: findings from China National Tobacco Cessation Cohort Study (CNTCCS)},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626004114?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...